Perlegen Raises $74 Million to Apply Pharmacogenomics to Late-Stage Drug Pipeline
Monday February 28, 1:54 pm ET
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Feb. 28, 2005--Perlegen Sciences, Inc. today announced the closing of a $74 million private placement of its Series D Preferred Stock with new and existing investors. The financing was led by CSK Venture Capital, and new investors included Brookside Capital, an affiliate of Bain Capital, Mizuho Securities, Glynn Capital Management, Cape Securities and several other U.S. and European institutional investors. Previous investors also participating in the financing included Dr. Alex Zaffaroni, Maverick Capital, Lombard Odier Darier Hentsch & Cie, Zesiger Capital, Sano Ventures, BSI SA, MPM BioEquities, SB Life Sciences, Unilever Ventures, Biofrontier Partners, Private Life Biomed, CMEA Ventures and Affymetrix. |
